Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: A population-based cohort study

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Der Zanden, Rogier Wvan ^a,b   De Vries, Frank ^a,b,c,d   Lalmohamed, Arief ^c,d   Driessen, Johanna H M ^a,b,c,d   De Boer, Anthonius ^c,d   Rohde, Gernot ^a   Neef, Cees ^a,b   Den Heijer, Casper ^a,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e South Limburg Public Health Service   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GROUPS BY AGE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; POPULATION RISK; SEX DIFFERENCE; TREATMENT WITHDRAWAL; VERY ELDERLY; ADOLESCENT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; RISK; YOUNG ADULT;

EID: 84948971364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139367     Document Type: Article

References (37)

1. Reinhold D, Biton A, Goihl A, Pieper S, Lendeckel U, Faust J et al. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann N Y Acad Sci. 2007; 1110: 402-9 PMID: 17911455
2. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005; 54(10): 2988-94. PMID: 16186403
3. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009; 25(10): 2401-11 doi: 10.1185/03007990903178735 PMID: 19650754
4. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011; 34(2): 369-74. doi: 10.2337/dc10-1771 PMID: 21270195
5. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1): 71-9. doi: 10.1136/thx.2009.129502 PMID: 20729232
6. Kolls JK. CD4(+) T-cell subsets and host defense in the lung. Immunol Rev. 2013; 252(1): 156-63. doi: 10.1111/imr.12030 PMID: 23405903
7. Eddens Taylor, and Kolls Jay K. 2012. Host Defenses against Bacterial Lower Respiratory Tract Infection. Current Opinion in Immunology 24 (4). Elsevier Ltd: 424-30. doi: 10.1016/j.coi.2012.07.005 PMID: 22841348
8. Takeda Pharma. n.d. "Vipidia (alogliptin) Summary of Product Characteristics (SmPC)." http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002182/WC500152271.pdf. Accessed 26 November 2014
9. Bristol-Myers Squibb. n.d. "Onglyza (saxagliptin) Summary of Product Characteristics (SmPC)." http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001039/WC500044316.pdf. Accessed 26 November 2014
10. Merck Sharp & Dohme. n.d. "Januvia (sitagliptin) Summary of Product Characteristics (SmPC)." http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000722/WC500039054.pdf. Accessed 26 November 2014
11. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28(10): 1556-68. PMID: 17157112
12. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: Pooled analysis of 25 clinical studies. Diabetes Ther. 2013; 4(1): 119-45. doi: 10.1007/s13300-013-0024-0 PMID: 23700194
13. Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: A meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012; 37(4): 386-98. doi: 10.1111/j.1365-2710.2011.01323.x PMID: 22191695
14. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab. 2012; 14(12): 1061-72. doi: 10.1111/j.1463-1326.2012.01610.x PMID: 22519906
15. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol. 2010; 69(1): 4-14. doi: 10.1111/j.1365-2125.2009.03537.x PMID: 20078607
16. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract. 2010; 60(572): E128-36. doi: 10.3399/bjgp10X483562 PMID: 20202356
17. Eppenga Willemijn L, Lalmohamed Arief, Geerts Arjen F, Derijks Hieronymus J, Wensing Michel, Egberts Antoine et al. Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users with Renal Impairment: A Population-Based Cohort Study. Diabetes Care 2014; 37(8) 2218-24. doi: 10.2337/dc13-3023 PMID: 24842984
18. Driessen JHM, van Onzenoort HAW, Henry RMA, Lalmohamed A, van den Bergh JP, Neef C et al. Use of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes Mellitus and Risk of Fracture. Bone 2014; 68: 124-30. doi: 10.1016/j.bone.2014.07.030 PMID: 25093264
19. Peeters PJ, Bazelier MT, Leufkens HG, de Vries F, De Bruin ML. The risk of colorectal cancer in patients with type 2 diabetes: Associations with treatment stage and obesity. Diabetes Care. 2015; 38 (3): 495-502. doi: 10.2337/dc14-1175 PMID: 25552419
20. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax.2006; 61(11): 957-61. PMID: 16809409
21. Anonymous. 2014. "WHOCC-ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health." http://www.whocc.no/atc-ddd-index/. Accessed 16 April 2015
22. Faillie JL, Filion KB, Patenaude V, Ernst P, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17 (4): 379-85. doi: 10.1111/dom.12431 PMID: 25581902
23. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: The General Practice Research Database. Int J Epidemiol. 2006; 35(5): 1301-8. PMID: 17053011
24. de Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: Three studies, same database, two answers. Osteoporos Int. 2011; 22(5): 1641-2. doi: 10.1007/s00198-010-1323-1 PMID: 20563562
25. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;( 2): CD006739. doi: 10.1002/14651858. CD006739.pub2 PMID: 18425967
26. Amori, Renee E, Joseph Lau, and Pittas Anastassios G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-Analysis. JAMA 2007; 298(2): 194-206. PMID: 17622601
27. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ 2012; 344: E1369. doi: 10.1136/bmj.e1369 PMID: 22411919
28. White PC, Chamberlain-Shea H, de la Morena MT. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. J Diabetes Complications. 2010; 24(3): 209-13. doi: 10.1016/j. jdiacomp.2009.09.001 PMID: 19854074
29. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998; 161: 55-70 PMID: 9553764
30. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013 Jun; 98(6): 2553-61 doi: 10.1210/jc.2012-4288 PMID: 23539735
31. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004; 350(24): 2487-98. PMID: 15190141
32. Fan H, Yan S, Stehling S, Marguet D, Schuppaw D, Reutter W. Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Adv Exp Med Biol. 2003; 524: 165-74 PMID: 12675236
33. von Bonin A, Hühn J, Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative Tcell activation pathway. Immunol Rev. 1998; 161: 43-53. PMID: 9553763
34. Zhang H, Chen Y, Keane FM, Gorrell MD. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9. Mol Cancer Res. 2013 Dec; 11(12): 1487-96. doi: 10.1158/1541-7786. MCR-13-0272 PMID: 24038034
35. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009 Nov; 58(11): 1723-47. doi: 10.1007/s00262-009-0728-1 PMID: 19557413
36. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: A literature review. Eur J Clin Microbiol Infect Dis. 2014; 33(7): 1065-79. doi: 10.1007/s10096-014-2067-1 PMID: 24532008
37. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991; 10(4): 577-81 PMID: 2057656